...
首页> 外文期刊>Stem cells international >Mesenchymal Stem/Stromal Cells Derived from Induced Pluripotent Stem Cells Support CD34(pos) Hematopoietic Stem Cell Propagation and Suppress Inflammatory Reaction
【24h】

Mesenchymal Stem/Stromal Cells Derived from Induced Pluripotent Stem Cells Support CD34(pos) Hematopoietic Stem Cell Propagation and Suppress Inflammatory Reaction

机译:衍生自诱导多能干细胞的间充质茎/基质细胞支持CD34(POS)造血干细胞繁殖并抑制炎症反应

获取原文
获取原文并翻译 | 示例
           

摘要

Mesenchymal stem/stromal cells (MSCs) represent a promising cell source for research and therapeutic applications, but their restricted ex vivo propagation capabilities limit putative applications. Substantial self-renewing of stem cells can be achieved by reprogramming cells into induced pluripotent stem cells (iPSCs) that can be easily expanded as undifferentiated cells even in mass culture. Here, we investigated a differentiation protocol enabling the generation and selection of human iPSC-derived MSCs exhibiting relevant surface marker expression profiles (CD105 and CD73) and functional characteristics. We generated such iPSC-MSCs from fibroblasts and bone marrow MSCs utilizing two different reprogramming constructs. All such iPSC-MSCs exhibited the characteristics of normal bone marrow-derived (BM) MSCs. In direct comparison to BM-MSCs our iPSC-MSCs exhibited a similar surface marker expression profile but shorter doubling times without reaching senescence within 20 passages. Considering functional capabilities, iPSC-MSCs provided supportive feeder layer for CD34(+) hematopoietic stemcells' self-renewal and colony forming capacities. Furthermore, iPSC-MSCs gained immunomodulatory function to suppress CD4(+) cell proliferation, reduce proinflammatory cytokines in mixed lymphocyte reaction, and increase regulatory CD4(+)/CD69(+)/CD25(+) T-lymphocyte population. In conclusion, we generated fully functional MSCs from various iPSC lines irrespective of their starting cell source or reprogramming factor composition and we suggest that such iPSC-MSCs allow repetitive cell applications for advanced therapeutic approaches.
机译:间充质茎/基质细胞(MSCs)代表了用于研究和治疗应用的有前途的细胞来源,但其限制的离体传播能力限制推定应用。通过将细胞重编程为诱导多能干细胞(IPSC)可以实现基本的自我更新,即使在大规模培养中,可以容易地扩展为未分化的细胞。在这里,我们研究了一种差异化协议,使得能够产生和选择人IPSC衍生的MSCs,其表现出相关的表面标记表达谱(CD105和CD73)和功能特性。我们利用两种不同的重编程构建体产生了来自成纤维细胞和骨髓MSC的IPSC-MSC。所有此类IPSC-MSCs都表现出正常骨髓衍生(BM)MSCs的特征。与BM-MSC的直接比较,我们的IPSC-MSCs表现出类似的表面标记表达谱,但在20段通道内没有达到衰老的倍增时间较短。考虑功能性能力,IPSC-MSCS为CD34(+)造血溶剂的自我更新和菌落形成容量提供了支撑馈线层。此外,IPSC-MSCs获得免疫调节功能以抑制CD4(+)细胞增殖,减少混合淋巴细胞反应中的促炎细胞因子,并增加调节CD4(+)/ CD69(+)/ CD25(+)T淋巴细胞群。总之,我们从各种IPSC线产生完全功能的MSC,而不管其起始细胞源或重新编程因子组成,我们建议这种IPSC-MSCS允许重复的细胞应用进行高级治疗方法。

著录项

  • 来源
    《Stem cells international》 |2015年第3期|共14页
  • 作者单位

    Hannover Med Sch Cluster Of Excellence REBIRTH Dept Gastroenterol Hepatol &

    Endocrinol RG;

    Hannover Med Sch Cluster Of Excellence REBIRTH Dept Gastroenterol Hepatol &

    Endocrinol RG;

    DRK Inst Transfus Med &

    Immune Hematol Frankfurt Germany;

    Ludwig Maximilian Univ Hosp Dept Transfus Med Cell Therapy &

    Hemostaseol D-81377 Munich Germany;

    Hannover Med Sch Cluster Of Excellence REBIRTH Dept Gastroenterol Hepatol &

    Endocrinol RG;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物工程学(生物技术);
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号